A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers

Nhan T. Nguyen, Julie A. Vendrell, Coralie Poulard, B. Györffy, Sophie Goddard-Léon, Ivan Bièche, Laura Corbo, Muriel Le Romancer, Thomas Bachelot, Isabelle Treilleux, Pascale A. Cohen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We aimed at highlighting the role of ZNF217, a Krüppel-like finger protein, in Estrogen Receptor-α (ERα)-positive (ER+) and luminal breast cancers. Here we report for the first time that ZNF217 and ERα proteins bind to each other in both breast cancer cells and breast tumour samples, via the ERα hinge domain and the ZNF217 C-terminal domain. ZNF217 enhances the recruitment of ERα to its estrogen response elements (ERE) and the ERα-dependent transcription of the GREB1 estrogen-regulated gene. The prognostic power of ZNF217 mRNA expression levels is most discriminatory in breast cancers classified with a "good prognosis", particularly the Luminal-A subclass. A new immunohistochemistry ZNF217 index, based on nuclear and cytoplasmic ZNF217 staining, also allowed the identification of intermediate/poor relapse-free survivors in the Luminal-A subgroup. ZNF217 confers tamoxifen resistance in ER+ breast cancer cells and is a predictor of relapse under endocrine therapy in patients with ER+ breast cancer. ZNF217 thus allows the re-stratification of patients with ER+ breast cancers considered as cancers with good prognosis where no other biomarkers are currently available and widely used. Here we propose a model in ER+ breast cancer where ZNF217-driven aggressiveness incorporates ZNF217 as a positive enhancer of ERα direct genomic activity and where ZNF217 possesses its highest discriminatory prognostic value.

Original languageEnglish
Pages (from-to)1441-1457
Number of pages17
JournalMolecular Oncology
Volume8
Issue number8
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Estrogen Receptor alpha
Estrogen Receptors
Breast Neoplasms
Phenobarbital
Estrogens
Recurrence
Response Elements
Tamoxifen
Fingers
Survivors
Biomarkers
Immunohistochemistry
Staining and Labeling
Messenger RNA

Keywords

  • Biomarker
  • Breast cancer
  • Endocrine therapy resistance
  • Estrogen Receptor-α
  • Estrogen signalling
  • ZNF217

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Nguyen, N. T., Vendrell, J. A., Poulard, C., Györffy, B., Goddard-Léon, S., Bièche, I., ... Cohen, P. A. (2014). A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. Molecular Oncology, 8(8), 1441-1457. https://doi.org/10.1016/j.molonc.2014.05.013

A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. / Nguyen, Nhan T.; Vendrell, Julie A.; Poulard, Coralie; Györffy, B.; Goddard-Léon, Sophie; Bièche, Ivan; Corbo, Laura; Le Romancer, Muriel; Bachelot, Thomas; Treilleux, Isabelle; Cohen, Pascale A.

In: Molecular Oncology, Vol. 8, No. 8, 01.12.2014, p. 1441-1457.

Research output: Contribution to journalArticle

Nguyen, NT, Vendrell, JA, Poulard, C, Györffy, B, Goddard-Léon, S, Bièche, I, Corbo, L, Le Romancer, M, Bachelot, T, Treilleux, I & Cohen, PA 2014, 'A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers', Molecular Oncology, vol. 8, no. 8, pp. 1441-1457. https://doi.org/10.1016/j.molonc.2014.05.013
Nguyen, Nhan T. ; Vendrell, Julie A. ; Poulard, Coralie ; Györffy, B. ; Goddard-Léon, Sophie ; Bièche, Ivan ; Corbo, Laura ; Le Romancer, Muriel ; Bachelot, Thomas ; Treilleux, Isabelle ; Cohen, Pascale A. / A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. In: Molecular Oncology. 2014 ; Vol. 8, No. 8. pp. 1441-1457.
@article{b21c30860bea48079ba22f04a1ebe272,
title = "A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers",
abstract = "We aimed at highlighting the role of ZNF217, a Kr{\"u}ppel-like finger protein, in Estrogen Receptor-α (ERα)-positive (ER+) and luminal breast cancers. Here we report for the first time that ZNF217 and ERα proteins bind to each other in both breast cancer cells and breast tumour samples, via the ERα hinge domain and the ZNF217 C-terminal domain. ZNF217 enhances the recruitment of ERα to its estrogen response elements (ERE) and the ERα-dependent transcription of the GREB1 estrogen-regulated gene. The prognostic power of ZNF217 mRNA expression levels is most discriminatory in breast cancers classified with a {"}good prognosis{"}, particularly the Luminal-A subclass. A new immunohistochemistry ZNF217 index, based on nuclear and cytoplasmic ZNF217 staining, also allowed the identification of intermediate/poor relapse-free survivors in the Luminal-A subgroup. ZNF217 confers tamoxifen resistance in ER+ breast cancer cells and is a predictor of relapse under endocrine therapy in patients with ER+ breast cancer. ZNF217 thus allows the re-stratification of patients with ER+ breast cancers considered as cancers with good prognosis where no other biomarkers are currently available and widely used. Here we propose a model in ER+ breast cancer where ZNF217-driven aggressiveness incorporates ZNF217 as a positive enhancer of ERα direct genomic activity and where ZNF217 possesses its highest discriminatory prognostic value.",
keywords = "Biomarker, Breast cancer, Endocrine therapy resistance, Estrogen Receptor-α, Estrogen signalling, ZNF217",
author = "Nguyen, {Nhan T.} and Vendrell, {Julie A.} and Coralie Poulard and B. Gy{\"o}rffy and Sophie Goddard-L{\'e}on and Ivan Bi{\`e}che and Laura Corbo and {Le Romancer}, Muriel and Thomas Bachelot and Isabelle Treilleux and Cohen, {Pascale A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.molonc.2014.05.013",
language = "English",
volume = "8",
pages = "1441--1457",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers

AU - Nguyen, Nhan T.

AU - Vendrell, Julie A.

AU - Poulard, Coralie

AU - Györffy, B.

AU - Goddard-Léon, Sophie

AU - Bièche, Ivan

AU - Corbo, Laura

AU - Le Romancer, Muriel

AU - Bachelot, Thomas

AU - Treilleux, Isabelle

AU - Cohen, Pascale A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - We aimed at highlighting the role of ZNF217, a Krüppel-like finger protein, in Estrogen Receptor-α (ERα)-positive (ER+) and luminal breast cancers. Here we report for the first time that ZNF217 and ERα proteins bind to each other in both breast cancer cells and breast tumour samples, via the ERα hinge domain and the ZNF217 C-terminal domain. ZNF217 enhances the recruitment of ERα to its estrogen response elements (ERE) and the ERα-dependent transcription of the GREB1 estrogen-regulated gene. The prognostic power of ZNF217 mRNA expression levels is most discriminatory in breast cancers classified with a "good prognosis", particularly the Luminal-A subclass. A new immunohistochemistry ZNF217 index, based on nuclear and cytoplasmic ZNF217 staining, also allowed the identification of intermediate/poor relapse-free survivors in the Luminal-A subgroup. ZNF217 confers tamoxifen resistance in ER+ breast cancer cells and is a predictor of relapse under endocrine therapy in patients with ER+ breast cancer. ZNF217 thus allows the re-stratification of patients with ER+ breast cancers considered as cancers with good prognosis where no other biomarkers are currently available and widely used. Here we propose a model in ER+ breast cancer where ZNF217-driven aggressiveness incorporates ZNF217 as a positive enhancer of ERα direct genomic activity and where ZNF217 possesses its highest discriminatory prognostic value.

AB - We aimed at highlighting the role of ZNF217, a Krüppel-like finger protein, in Estrogen Receptor-α (ERα)-positive (ER+) and luminal breast cancers. Here we report for the first time that ZNF217 and ERα proteins bind to each other in both breast cancer cells and breast tumour samples, via the ERα hinge domain and the ZNF217 C-terminal domain. ZNF217 enhances the recruitment of ERα to its estrogen response elements (ERE) and the ERα-dependent transcription of the GREB1 estrogen-regulated gene. The prognostic power of ZNF217 mRNA expression levels is most discriminatory in breast cancers classified with a "good prognosis", particularly the Luminal-A subclass. A new immunohistochemistry ZNF217 index, based on nuclear and cytoplasmic ZNF217 staining, also allowed the identification of intermediate/poor relapse-free survivors in the Luminal-A subgroup. ZNF217 confers tamoxifen resistance in ER+ breast cancer cells and is a predictor of relapse under endocrine therapy in patients with ER+ breast cancer. ZNF217 thus allows the re-stratification of patients with ER+ breast cancers considered as cancers with good prognosis where no other biomarkers are currently available and widely used. Here we propose a model in ER+ breast cancer where ZNF217-driven aggressiveness incorporates ZNF217 as a positive enhancer of ERα direct genomic activity and where ZNF217 possesses its highest discriminatory prognostic value.

KW - Biomarker

KW - Breast cancer

KW - Endocrine therapy resistance

KW - Estrogen Receptor-α

KW - Estrogen signalling

KW - ZNF217

UR - http://www.scopus.com/inward/record.url?scp=84911966248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911966248&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.05.013

DO - 10.1016/j.molonc.2014.05.013

M3 - Article

VL - 8

SP - 1441

EP - 1457

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 8

ER -